This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

Do you have ovarian cancer that has come back after your first round of treatment? if so you may be able to participate in a research study to test if MIRV in combination with bevacizumab as maintenance therapy, can help to prevent your cancer from returning or delaying your cancer's return.

This study tests whether the investigational device CT-155 improves negative symptoms associated with schizophrenia.

To determine the effect of an FDA-approved drug on treating patients with severe strictures and Eosinophilic Esophagitis (EoE)

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

To determine the change from baseline to post-treatment values in HR-positive, HER2-negative invasive lobular carcinoma tissue derived from postmenopausal women awaiting definitive surgery or further treatment.

Researchers want to learn more a new medication that could be used to treat adults with Eosinophilic Esophagitis (also called "EoE").

To determine the difference in change in apoptosis between diagnosis and surgery as a function of ruxolitinib treatment versus placebo, among participants with high-risk or premalignant breast conditions.

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.

Have you been diagnosed with breast cancer with brain metastases? If so, you may be able to take part in a research study looking at the safety of giving a new drug called olaparib concurrently (at the same time) with stereotactic radiosurgery, followed by immunotherapy and chemotherapy, to patients with breast cancer with brain metastases.